A- A A+

Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada. 

Cui Z, Hayashi K, Bach P, Milloy MJ, Kerr T. 

J Subst Use Addict Treat. 2023 Jan 18:208956. doi: 10.1016/j.josat.2023.208956. Epub ahead of print. PMID: 36804867.



Australien. Methamphetamin: The Tina Trial

The Tina Trial is a clinical trial designed to see whether mirtazapine, an antidepressant medication, can help people reduce their use of methamphetamine (ice, crystal meth). Two previous small trials in the USA found that mirtazapine helped people to reduce their methamphetamine use and improved their mood. We want to find out whether mirtazapine can be used in routine clinical care in Australia. (NDARC - National Drug and Alcohol Research Centre, Australien, Februar 2023)


Amphetamines modulate fentanyl-depressed respiration in a bidirectional manner. 

Elder HJ, Varshneya NB, Walentiny DM, Beardsley PM. 

Drug Alcohol Depend. 2023 Feb 1;243:109740. doi: 10.1016/j.drugalcdep.2022.109740. Epub 2022 Dec 16. PMID: 36608481; PMCID: PMC9881117.


Splice-Site Variants in the Gene Encoding GABA-A Receptor Delta Subunit Are Associated with Amphetamine Use in Patients under Methadone Maintenance Treatment. 

Lin YF, Chou WH, Liu TH, Fang CP, Kuo HW, Kuo PH, Tsai SJ, Wang SC, Chung RH, Tsou HH, Chen ACH, Liu YL. 

Int J Mol Sci. 2022 Dec 31;24(1):721. doi: 10.3390/ijms24010721. PMID: 36614162; PMCID: PMC9820820.


Reduced neural functional connectivity during working memory performance in methamphetamine use disorder. 

Nestor LJ, Ghahremani DG, London ED. 

Drug Alcohol Depend. 2023 Feb 1;243:109764. doi: 10.1016/j.drugalcdep.2023.109764. Epub 2023 Jan 4. PMID: 36610253.


Methamphetamine-associated heart failure: a systematic review of observational studies

Manja V, Nrusimha A, Gao Y, et al

Heart, Published Online First: 01 December 2022. doi: 10.1136/heartjnl-2022-321610 


Herzinsuffizienzen durch Methkonsum nehmen weltweit und in allen Bevölkerungsschichten zu

Menlo Park – Immer mehr Menschen weltweit sterben an Herzinsuffizienzen, die mit dem Missbrauch von Methamphetamin („Meth“, „Crystal Meth“) assoziiert sind. Und betroffen ist davon längst ein breites Spektrum an sozialen, ökonomischen und ethnischen Gruppen, wie ein im Fachblatt Heart veröffentlichter Review zeigt (2022; DOI: 10.1136/heartjnl-2022-321610). (aerzteblatt.de, 06.12.2022)


Stimulant abuse as a coping strategy-Forensic and criminal consequences of stimulant abuse for neuroenhancement. 

Dominik P, Waßmer MP, Soyka M, Franke AG. 

Front Public Health. 2022 Oct 28;10:1028654. doi: 10.3389/fpubh.2022.1028654. PMID: 36388290; PMCID: PMC9650539.


Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial. 

Acheson LS, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried KJ. 

Drug Alcohol Depend. 2022 Nov 7;241:109692. doi: 10.1016/j.drugalcdep.2022.109692. Epub ahead of print. PMID: 36399936.


The Ratio of Second and Fourth Digit Length: A Biomarker for Methamphetamine Dependence? 

Kim Y, Won SD, Kwon H, Han C. 

Clin Psychopharmacol Neurosci. 2022 Nov 30;20(4):694-700. doi: 10.9758/cpn.2022.20.4.694. PMID: 36263644; PMCID: PMC9606433.


Minimising the Harms from Methamphetamine. The Helen Clark Foundation and New Zealand Drug Foundation, Wellington.

Yasbek, P., Mercier K., Dr Elder, H., Dr Crossin, R., Prof. Baker, M. (2022). 


Pharmacotherapies for Methamphetamine Withdrawal (Video)

This Video Abstract explores what we know about methamphetamine withdrawal, and how treating it might be approached.

Using the results of a systematic review and meta-analysis, we discuss what medications have been trialled to date, whether or not they worked, and the impact of these results in clinical practice. (NCCRAD – National Centre for Clinical Research on Emerging Drugs, Australien, JULI 2022, VIDEO, 03:41)


Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials. 

Acheson, LS, Williams, BH, Farrell, M, McKetin, R, Ezard, N, Siefried, KJ. 

Drug Alcohol Rev. 2022. doi.org/10.1111/dar.13511


The practice and embodiment of "goofballs": A qualitative study exploring the co-injection of methamphetamines and opioids. 

Ivsins A, Fleming T, Barker A, Mansoor M, Thakarar K, Sue K, McNeil R. 

Int J Drug Policy. 2022 Jul 10;107:103791. doi: 10.1016/j.drugpo.2022.103791. Epub ahead of print. PMID: 35830749.


Over One Hundred Years of MDMA Research

3,4-Methylenedioxymethamphetamine (MDMA), also known as Mandy, Molly, Ecstasy or ‘E’, is a class A drug known for inducing feelings of happiness, chattiness, liveliness, and overall feelings of ecstasy, making it a common adjacent to enhancing raves, clubs and parties. Lesser known, MDMA has historically also been used in research to aid in therapy until it became illegal. More recently, there has been a shift back to focusing on the use of MDMA in medical research. (Drug Science, UK, 29.06.2022)


Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts. 

Daiwile AP, Jayanthi S, Cadet JL. 

Neurosci Biobehav Rev. 2022 Jun;137:104674. doi: 10.1016/j.neubiorev.2022.104674. Epub 2022 Apr 20. PMID: 35452744; PMCID: PMC9119944.


Trends in Methamphetamine Use in the Mainland of China, 2006-2015.

Zhang B, Yan X, Li Y, Zhu H, Lu Z, Jia Z.

Front Public Health. 2022 Apr 28;10:852837. doi: 10.3389/fpubh.2022.852837. PMID: 35570894; PMCID: PMC9096246.


Identifying behaviours for survival and wellness among people who use methamphetamine with opioids in British Columbia: a qualitative study. 

Corser J, Palis H, Fleury M, Lamb J, Lock K, McDougall J, Mehta A, Newman C, Spence H, Buxton JA. 

Harm Reduct J. 2022 May 19;19(1):46. doi: 10.1186/s12954-022-00630-8. PMID: 35590375; PMCID: PMC9118627.


How dangerous is MDMA? 

Frost J. 

Tidsskr Nor Laegeforen. 2022 May 19;142(8). English, Norwegian. doi: 10.4045/tidsskr.22.0309. PMID: 35635415.


Signals of increasing co-use of stimulants and opioids from online drug forum data. 

Sarker A, Al-Garadi MA, Ge Y, Nataraj N, Jones CM, Sumner SA. 

Harm Reduct J. 2022 May 25;19(1):51. doi: 10.1186/s12954-022-00628-2. PMID: 35614501; PMCID: PMC9131693.


UNODC. Synthetic Drugs in East and Southeast Asia Latest developments and challenges - 2022

United Nations Office on Drugs and Crime (UNODC), Global SMART Programme, 2022


Patterns of and Rationale for the Co-use of Methamphetamine and Opioids: Findings From Qualitative Interviews in New Mexico and Nevada. 

Rhed BD, Harding RW, Marks C, Wagner KT, Fiuty P, Page K, Wagner KD. 

Front Psychiatry. 2022 Mar 28;13:824940. doi: 10.3389/fpsyt.2022.824940. PMID: 35418887; PMCID: PMC8995976.


Different phases of ATS use call for different interventions: a large qualitative study in Europe. 

Liebregts, N., Rigoni, R., Petruželka, B. et al.

Harm Reduct J 19, 36 (2022). doi.org/10.1186/s12954-022-00617-5


An adaptive design to screen, treat, and retain people with opioid use disorders who use methamphetamine in methadone clinics (STAR-OM): study protocol of a clinical trial. 

Giang LM, Trang NT, Diep NB, Thuy DTD, Thuy DT, Hoe HD, Van HTH, Truc TT, Nguyen HH, Lai NL, Linh PTD, Vi VTT, Reback CJ, Leibowitz A, Li L, Lin C, Li M, Do Van Dung, Shoptaw S. 

Trials. 2022 Apr 23;23(1):342. doi: 10.1186/s13063-022-06278-w. PMID: 35461300; PMCID: PMC9034071.


The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. 

Nicholas CR, Wang JB, Coker A, Mitchell JM, Klaire SS, Yazar-Klosinski B, Emerson A, Brown RT, Doblin R. 

Drug Alcohol Depend. 2022 Apr 1;233:109356. doi: 10.1016/j.drugalcdep.2022.109356. Epub 2022 Feb 11. PMID: 35286849.


Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. 

Marseille E, Mitchell JM, Kahn JG (2022) 

PLoS ONE 17(2): e0263252. doi.org/10.1371/journal.pone.0263252


Current Situation of Methamphetamine Abuse and Related Research Progress. 

Hong SJ, Shen BY, Sun RJ, Yang GM, Duan CM, Nie QY, Zhang CB, Dong WJ, Yu H, Wang S, Liu PL, Wen PY, Li LH. 

Fa Yi Xue Za Zhi. 2021 Dec 25;37(6):763-775. English, Chinese. doi: 10.12116/j.issn.1004-5619.2021.310202. PMID: 35243841.


Oxytocin, a Novel Treatment for Methamphetamine Use Disorder. 

Edinoff AN, Thompson E, Merriman CE, Alvarez MR, Alpaugh ES, Cornett EM, Murnane KS, Kozinn RL, Shah-Bruce M, Kaye AM, Kaye AD. 

Neurol Int. 2022 Jan 30;14(1):186-198. doi: 10.3390/neurolint14010015. PMID: 35225885; PMCID: PMC8883935.


Shifting Pathways of Stimulant Use Among Individuals With Opioid Use Disorder: A Retrospective Analysis of the Last Thirty Years. 

Ellis MS, Kasper ZA, Scroggins S. 

Front Psychiatry. 2021 Dec 20;12:786056. doi: 10.3389/fpsyt.2021.786056. PMID: 34987431; PMCID: PMC8721201.


Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada. 

Morin KA, Vojtesek F, Acharya S, Marsh DC. 

Front Psychiatry. 2021 Dec 20;12:782066. doi: 10.3389/fpsyt.2021.782066. PMID: 34987430; PMCID: PMC8721960.